Under the combination therapy, there is a larger viral infectivity range under which the tumor can be eliminated, increasing the possibility of developing a sufficiently infectious virus to combine with anti-PD-1 to eliminate murine GBM. This evidence concerns the gene PDCD1 and glioblastoma.